Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Identifieur interne : 000159 ( Main/Exploration ); précédent : 000158; suivant : 000160Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Auteurs : Tarun Bhatnagar [Inde] ; Manoj V. Murhekar [Inde] ; Manish Soneja [Inde] ; Nivedita Gupta [Inde] ; Sidhartha Giri [Inde] ; Naveet Wig [Inde] ; Raman Gangakhedkar [Inde]Source :
- The Indian journal of medical research [ 0971-5916 ] ; 2020.
Abstract
As of February 29, 2020, more than 85,000 cases of coronavirus disease 2019 (COVID-19) have been reported from China and 53 other countries with 2,924 deaths. On January 30, 2020, the first laboratory-confirmed case of COVID was reported from Kerala, India. In view of the earlier evidence about effectiveness of repurposed lopinavir/ritonavir against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus (CoV), as well as preliminary docking studies conducted by the ICMR-National Institute of Virology, Pune, the Central Drugs Standard Control Organization approved the restricted public health use of lopinavir/ritonavir combination amongst symptomatic COVID-19 patients detected in the country. Hospitalized adult patients with laboratory-confirmed SARS-CoV-2 infection with any one of the following criteria will be eligible to receive lopinavir/ritonavir for 14 days after obtaining written informed consent: (i) respiratory distress with respiratory rate ≥22/min or SpO2 of <94 per cent; (ii) lung parenchymal infiltrates on chest X-ray; (iii) hypotension defined as systolic blood pressure <90 mmHg or need for vasopressor/inotropic medication; (iv) new-onset organ dysfunction; and (v) high-risk groups - age >60 yr, diabetes mellitus, renal failure, chronic lung disease and immunocompromised persons. Patients will be monitored to document clinical (hospital length of stay and mortality at 14, 28 and 90 days), laboratory (presence of viral RNA in serial throat swab samples) and safety (adverse events and serious adverse events) outcomes. Treatment outcomes amongst initial cases would be useful in providing guidance about the clinical management of patients with COVID-19. If found useful in managing initial SARS-CoV-2-infected patients, further evaluation using a randomized control trial design is warranted to guide future therapeutic use of this combination.
DOI: 10.4103/ijmr.IJMR_502_20
PubMed: 32202256
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000139
- to stream PubMed, to step Curation: 000139
- to stream PubMed, to step Checkpoint: 000158
- to stream Ncbi, to step Merge: 002635
- to stream Ncbi, to step Curation: 002635
- to stream Ncbi, to step Checkpoint: 002635
- to stream Main, to step Merge: 000162
- to stream Main, to step Curation: 000159
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.</title><author><name sortKey="Bhatnagar, Tarun" sort="Bhatnagar, Tarun" uniqKey="Bhatnagar T" first="Tarun" last="Bhatnagar">Tarun Bhatnagar</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>School of Public Health, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Murhekar, Manoj V" sort="Murhekar, Manoj V" uniqKey="Murhekar M" first="Manoj V" last="Murhekar">Manoj V. Murhekar</name><affiliation wicri:level="1"><nlm:affiliation>ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Soneja, Manish" sort="Soneja, Manish" uniqKey="Soneja M" first="Manish" last="Soneja">Manish Soneja</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Medicine, All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Gupta, Nivedita" sort="Gupta, Nivedita" uniqKey="Gupta N" first="Nivedita" last="Gupta">Nivedita Gupta</name><affiliation wicri:level="1"><nlm:affiliation>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Giri, Sidhartha" sort="Giri, Sidhartha" uniqKey="Giri S" first="Sidhartha" last="Giri">Sidhartha Giri</name><affiliation wicri:level="1"><nlm:affiliation>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Wig, Naveet" sort="Wig, Naveet" uniqKey="Wig N" first="Naveet" last="Wig">Naveet Wig</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Medicine, All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Gangakhedkar, Raman" sort="Gangakhedkar, Raman" uniqKey="Gangakhedkar R" first="Raman" last="Gangakhedkar">Raman Gangakhedkar</name><affiliation wicri:level="1"><nlm:affiliation>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32202256</idno><idno type="pmid">32202256</idno><idno type="doi">10.4103/ijmr.IJMR_502_20</idno><idno type="wicri:Area/PubMed/Corpus">000139</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000139</idno><idno type="wicri:Area/PubMed/Curation">000139</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000139</idno><idno type="wicri:Area/PubMed/Checkpoint">000158</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000158</idno><idno type="wicri:Area/Ncbi/Merge">002635</idno><idno type="wicri:Area/Ncbi/Curation">002635</idno><idno type="wicri:Area/Ncbi/Checkpoint">002635</idno><idno type="wicri:doubleKey">0971-5916:2020:Bhatnagar T:lopinavir:ritonavir:combination</idno><idno type="wicri:Area/Main/Merge">000162</idno><idno type="wicri:Area/Main/Curation">000159</idno><idno type="wicri:Area/Main/Exploration">000159</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.</title><author><name sortKey="Bhatnagar, Tarun" sort="Bhatnagar, Tarun" uniqKey="Bhatnagar T" first="Tarun" last="Bhatnagar">Tarun Bhatnagar</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>School of Public Health, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Murhekar, Manoj V" sort="Murhekar, Manoj V" uniqKey="Murhekar M" first="Manoj V" last="Murhekar">Manoj V. Murhekar</name><affiliation wicri:level="1"><nlm:affiliation>ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu</wicri:regionArea><wicri:noRegion>Tamil Nadu</wicri:noRegion></affiliation></author><author><name sortKey="Soneja, Manish" sort="Soneja, Manish" uniqKey="Soneja M" first="Manish" last="Soneja">Manish Soneja</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Medicine, All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Gupta, Nivedita" sort="Gupta, Nivedita" uniqKey="Gupta N" first="Nivedita" last="Gupta">Nivedita Gupta</name><affiliation wicri:level="1"><nlm:affiliation>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Giri, Sidhartha" sort="Giri, Sidhartha" uniqKey="Giri S" first="Sidhartha" last="Giri">Sidhartha Giri</name><affiliation wicri:level="1"><nlm:affiliation>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Wig, Naveet" sort="Wig, Naveet" uniqKey="Wig N" first="Naveet" last="Wig">Naveet Wig</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Medicine, All India Institute of Medical Sciences, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Gangakhedkar, Raman" sort="Gangakhedkar, Raman" uniqKey="Gangakhedkar R" first="Raman" last="Gangakhedkar">Raman Gangakhedkar</name><affiliation wicri:level="1"><nlm:affiliation>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Indian journal of medical research</title><idno type="ISSN">0971-5916</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As of February 29, 2020, more than 85,000 cases of coronavirus disease 2019 (COVID-19) have been reported from China and 53 other countries with 2,924 deaths. On January 30, 2020, the first laboratory-confirmed case of COVID was reported from Kerala, India. In view of the earlier evidence about effectiveness of repurposed lopinavir/ritonavir against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus (CoV), as well as preliminary docking studies conducted by the ICMR-National Institute of Virology, Pune, the Central Drugs Standard Control Organization approved the restricted public health use of lopinavir/ritonavir combination amongst symptomatic COVID-19 patients detected in the country. Hospitalized adult patients with laboratory-confirmed SARS-CoV-2 infection with any one of the following criteria will be eligible to receive lopinavir/ritonavir for 14 days after obtaining written informed consent: (i) respiratory distress with respiratory rate ≥22/min or SpO2 of <94 per cent; (ii) lung parenchymal infiltrates on chest X-ray; (iii) hypotension defined as systolic blood pressure <90 mmHg or need for vasopressor/inotropic medication; (iv) new-onset organ dysfunction; and (v) high-risk groups - age >60 yr, diabetes mellitus, renal failure, chronic lung disease and immunocompromised persons. Patients will be monitored to document clinical (hospital length of stay and mortality at 14, 28 and 90 days), laboratory (presence of viral RNA in serial throat swab samples) and safety (adverse events and serious adverse events) outcomes. Treatment outcomes amongst initial cases would be useful in providing guidance about the clinical management of patients with COVID-19. If found useful in managing initial SARS-CoV-2-infected patients, further evaluation using a randomized control trial design is warranted to guide future therapeutic use of this combination.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Bhatnagar, Tarun" sort="Bhatnagar, Tarun" uniqKey="Bhatnagar T" first="Tarun" last="Bhatnagar">Tarun Bhatnagar</name></noRegion><name sortKey="Gangakhedkar, Raman" sort="Gangakhedkar, Raman" uniqKey="Gangakhedkar R" first="Raman" last="Gangakhedkar">Raman Gangakhedkar</name><name sortKey="Giri, Sidhartha" sort="Giri, Sidhartha" uniqKey="Giri S" first="Sidhartha" last="Giri">Sidhartha Giri</name><name sortKey="Gupta, Nivedita" sort="Gupta, Nivedita" uniqKey="Gupta N" first="Nivedita" last="Gupta">Nivedita Gupta</name><name sortKey="Murhekar, Manoj V" sort="Murhekar, Manoj V" uniqKey="Murhekar M" first="Manoj V" last="Murhekar">Manoj V. Murhekar</name><name sortKey="Soneja, Manish" sort="Soneja, Manish" uniqKey="Soneja M" first="Manish" last="Soneja">Manish Soneja</name><name sortKey="Wig, Naveet" sort="Wig, Naveet" uniqKey="Wig N" first="Naveet" last="Wig">Naveet Wig</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000159 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000159 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32202256
|texte= Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32202256" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |